<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918043</url>
  </required_header>
  <id_info>
    <org_study_id>HUS/222/2021</org_study_id>
    <nct_id>NCT04918043</nct_id>
  </id_info>
  <brief_title>Alcohol Use During Pregnancy in Finland According to Meconium Samples</brief_title>
  <acronym>RASMEK21</acronym>
  <official_title>Raskaudenaikaiset Elintavat ja Etyyliglukuronidin Esiintyminen Mekoniumissa Suomessa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanna Kahila</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lastentautien tutkimussäätiö</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Meconium samples are collected anonymously from newborns in Helsinki University Hospital&#xD;
      maternity ward. The study tries to to find how many women continue to use alcohol during the&#xD;
      second half of the pregnancy. Meconium samples are tested for ethylglucuronide (EtG), a&#xD;
      metabolite of ethanol, that accumulates in the meconium. Altogether 1000 samples are taken.&#xD;
      The sample results are compared to anonymously answered questionnaire about alcohol use.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>EtG</measure>
    <time_frame>Once</time_frame>
    <description>The meconium samples from newborns are tested for ethyl glucuronide using LC-MS/MS mass spectrometry.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Fetal Alcohol Spectrum Disorders</condition>
  <arm_group>
    <arm_group_label>HUCS, NKL</arm_group_label>
    <description>Newborns and their mothers at the Helsinki University Central Hospital maternity ward.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      meconium&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of the newborn babies that are born at the Helsinki&#xD;
        University Central hospital maternity ward.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  newborn baby&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanna Kahila, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HUCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikko Koivu-Jolma</last_name>
    <phone>+358414873836</phone>
    <email>mikko.koivu-jolma@helsinki.fi</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>May 30, 2021</last_update_submitted>
  <last_update_submitted_qc>May 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Hanna Kahila</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Alcohol Spectrum Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All anonymous IPD will be shared with the modelling source code.</ipd_description>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>6 months after the publication</ipd_time_frame>
    <ipd_access_criteria>Scientific study, policy making</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

